Citi raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $46 from $38 and keeps a Buy rating on the shares. Citi also placed an “upside 90-day catalyst watch” on Agios. The firm expects “regulatory clarity” after the company provides details of its FDA meeting to discuss mitapivat in sickle cell disease. The analyst believes a favorable outcome is more likely than not.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios Pharmaceuticals Pyrukynd approved for adults in UAE
- Agios Pharmaceuticals Signals Confident Path After AQVESME Win
- Regulatory Delays Threaten Agios Pharmaceuticals’ Drug Pipeline, Costs and Revenue Outlook
- Buy Rating Backed by Strong Q4 Execution, Early Aqvesme Momentum, and Multi-Asset Clinical Catalyst Upside
- Agios Pharmaceuticals files automatic mixed securities shelf